Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
What's A Decent FICO rating? - 2At least 18 Palestinians killed in latest clashes in Gaza
- 3From invasive species tracking to water security – what’s lost with federal funding cuts at US Climate Adaptation Science Centers
- 4How AI fixed the James Webb Space Telescope's blurry vision
- 5This Unique National Park In Canada Is Famous For Its Otherworldly Limestone Monoliths
- Mars spacecraft images pinpoint comet 3I/ATLAS's path with 10x higher accuracy. This could help us protect Earth someday
- Figure out How to Pick the Right Toothbrush for You
- Figure out How to Score Huge with Open Record Rewards
- Accomplishing Balance between fun and serious activities: Procedures for a Better Life
- Instructions to Construct an Organization While Chasing after a Web-based Degree
- Watch the Geminid meteor shower peak tonight from the comfort of home with this free livestream
- Instructions to Distinguish the Wellbeing Dangers Related with 5G Pinnacles
- Watch Rocket Lab launch Japanese technology-demonstrating satellite to orbit tonight
- Gauging the Upsides and downsides of Visas: A Complete Aide
